Results 61 to 70 of about 411,749 (186)

Detemir insulin for the treatment of diabetes mellitus in dogs

open access: yes, 2015
Objective-To investigate the effects of insulin detemir in dogs with diabetes mellitus. Design-Prospective, uncontrolled clinical trial. Animals-10 client-owned dogs with naturally occurring diabetes mellitus.
Fracassi, F   +5 more
core   +1 more source

Metabolic parameters of continuously applied regular insulin or insulin detemir by using micro-osmotic pumps.

open access: yes, 2016
(A) Plasma insulin levels following implantation of micro-osmotic pumps containing either regular insulin, insulin detemir or saline. (B-D) Blood glucose concentrations (B), plasma glucagon levels (C) and body weight (D) of mice implanted with micro ...
Anita M. Hennige (36355)   +3 more
core   +1 more source

Metabolic parameters and beta activity during infusion of human insulin, insulin detemir and saline in 10 overweight individuals.

open access: yes, 2013
A: Plasma human insulin and total serum insulin detemir concentrations. Similar profiles of plasma/serum levels (Mean±SE) of human insulin and insulin detemir were achieved with both insulins.
Niels Birbaumer (36361)   +9 more
core   +1 more source

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A 1 chieve study

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66 726) in routine clinical care ...
Farida Ajdi
doaj   +1 more source

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

open access: yesVascular Health and Risk Management, 2010
Katarina RaslovaMetabolic Center Ltd and Slovak Medical University, Bratislava, Slovak RepublicAbstract: Basal insulin analogs are used to minimize unpredictable processes of NPH insulin.
Katarina Raslova
doaj  

Effect of Insulin Detemir (Levemir®) on Risk of Hypoglycaemia and Glycaemic Parameters: Experience from Real Life Practice in Indonesian Patients with Diabetes Mellitus

open access: yesJournal of the ASEAN Federation of Endocrine Societies
Objective. To evaluate the safety and efficacy of insulin detemir in patients with diabetes mellitus in Indonesia.   Methods. This was a multi-centre, prospective, 12-week observational study in patients with diabetes mellitus conducted in Indonesia. 
Pradana Soewondo, Anand Jain
doaj   +1 more source

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A 1 chieve study

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Background: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Abhay Kumar Sahoo   +4 more
doaj   +1 more source

Differences in Effect of Insulin Detemir and NPH Insulin on Glucose and Lipid Metabolism. [PDF]

open access: yes, 2020
Insulin detemir has a 14C fatty acid chain, which associates with free fatty acid binding sites on albumin. Capillary endothelial cells in adipose tissue and muscle may limit transfer of insulin detemir from the circulation into the extravascular ...
Hodern, Sara Victoria Margaret.
core  

Flying under the radar: treatment of refractory hyperglycemia

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2016
Clinicians are often presented with the scenario of what to do when one medication in a drug class has failed a therapeutic trial on a patient. We encountered a patient who developed profound resistance to glargine, aspart and regular insulin, but had a ...
S M Kandel, J A Cosgriff
doaj   +1 more source

Home - About - Disclaimer - Privacy